TY - JOUR T1 - An epithelial microRNA upregulates airway IL-25 and TSLP expression in type 2-high asthma via targeting CD39-extracellular ATP axis JF - medRxiv DO - 10.1101/2020.09.07.20188987 SP - 2020.09.07.20188987 AU - Kan Zhang AU - Yuchen Feng AU - Yuxia Liang AU - Wenliang Wu AU - Chenli Chang AU - Dian Chen AU - Shengchong Chen AU - Lingling Yi AU - Guohua Zhen Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/09/09/2020.09.07.20188987.abstract N2 - The presence of type 2 inflammation is a prominent endotype of asthma. Airway epithelial cell-derived cytokines IL-25, IL-33 and TSLP initiate type 2 inflammation. However, the upstream signaling pathway regulating these cytokines’ expression remains elusive. We identified a small set of epithelial microRNAs differentially expressed between type 2-low and –high asthma patients. MiR-206 was the most highly expressed microRNA in type 2-high asthma relative to type 2-low asthma, but was downregulated in both asthma subsets compared to control subjects. CD39, an ecto-nucleotidase degrading extracellular ATP, was a target of miR-206 and upregulated in asthma. In cultured human bronchial epithelial cells, allergen-induced rapid accumulation of extracellular ATP was responsible for miR-206 downregulation and CD39 upregulation, suggesting a protective mechanism to eliminate excessive ATP. Importantly, BALF ATP levels were increased in asthma patients, and strongly correlated with elevated IL-25 and TSLP expression in type 2-high asthma. Intriguingly, inhibition of airway miR-206 increased Cd39 expression, suppressed airway ATP accumulation and Il-25, Il-33, Tslp expression, and alleviated type 2 inflammation in a mouse model of asthma. In contrast, airway miR-206 overexpression had opposite effects. Taken together, airway epithelial miR-206 upregulates IL-25, TSLP expression via targeting CD39-extracellular ATP axis in type 2-high asthma.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by National Natural Science Foundation of China (grant 91742108, 81670019), National Key Research and Development Program of China (2016YFC1304400), and Hubei Province Natural Science Foundation (grant 2017CFA016).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Human and mouse studies were approved by the ethics committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript are available. The array data are available at GEO (http://www.ncbi.nlm.nih.gov/geo/, accession number GSE142237). http://www.ncbi.nlm.nih.gov/geo/ ER -